Accumetrics teams with Daiichi, Lilly for platelet function testing education
Accumetrics, Daiichi Sankyo and Eli Lilly have entered into a U.S. collaboration to raise awareness about antiplatelet therapy and the role of platelet function testing.
Factors including a patient’s genetic make-up, diabetic status, age, weight and the use of certain other medications metabolized through the cytochrome P450 pathway in the body may influence patient response to antiplatelet medicines. Therefore, the companies said it is “important that physicians understand their options to determine if their use of a specific antiplatelet medicine is having its intended effect.”
This collaborative program will work to provide healthcare professionals information about the factors that affect response to antiplatelet medication and how platelet function testing works. Platelet function testing can be measured at the point of care and provides insight to physicians about the antiplatelet effect of a medication.
Factors including a patient’s genetic make-up, diabetic status, age, weight and the use of certain other medications metabolized through the cytochrome P450 pathway in the body may influence patient response to antiplatelet medicines. Therefore, the companies said it is “important that physicians understand their options to determine if their use of a specific antiplatelet medicine is having its intended effect.”
This collaborative program will work to provide healthcare professionals information about the factors that affect response to antiplatelet medication and how platelet function testing works. Platelet function testing can be measured at the point of care and provides insight to physicians about the antiplatelet effect of a medication.